BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person ImmuneBD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune

BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

2025/12/18 20:15
Okuma süresi: 4 dk
Bu içerikle ilgili geri bildirim veya endişeleriniz için lütfen crypto.news@mexc.com üzerinden bizimle iletişime geçin.

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study

FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance research in deep human immune profiling and support the development of immune-mediated therapies.

The collaboration includes developing and validating a high-parameter flow cytometry panel that can capture key functional pathways in whole blood, including phosphorylation markers, which provide powerful insight into how single cells respond to drugs or disease states. The panel will support a planned 1,000-patient immune profiling study, in partnership with the Penn Colton Center for Autoimmunity, expected to start this summer. The project will leverage the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, BD reagents, software and informatics, with BD teams managing reagents, instrumentation, and spectral data algorithms, and I3H teams serving as scientific and clinical leads. The team intends to publish a peer-reviewed manuscript describing the results of the study.

“This project demonstrates the power of collaboration between academia and industry,” said Dr. E. John Wherry, PhD, the Richard and Barbara Schiffrin President’s Distinguished Professor, director of the Institute for Immunology and Immune Health at the University of Pennsylvania, and the director of the Colton Consortium for Autoimmunity. “We are bringing together cross-functional experts to transform human immune profiling for maximum impact, enabling deeper insights from our immune cells that could accelerate development of precise medical treatments.”

The collaboration reflects a shared vision of unlocking the power of the human immune system to advance science and health. It is made possible by the BD FACSDiscover™ A8 Cell Analyzer, which is the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, and the new BD Horizon™ Chroma solution for dried high-parameter panels. The project supports the commitment of both organizations to contribute to the research community through collaboration and knowledge sharing.

“High-parameter single-cell studies of this kind, once considered infeasible, are increasingly becoming central to better understanding the human immune system,” said Steve Conly, worldwide president of BD Biosciences. “Our ecosystem of industry-leading BD flow cytometers, single-cell systems, reagents, software and informatics, provide a critical missing puzzle piece that can support the important work of organizations like I3H to translate and deliver immunological insights into quantitative, actionable information for discovery and clinical care teams around the world.”

More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:

Media:

Investors:

Fallon McLoughlin

Adam Reiffe

Director, Public Relations

VP, Investor Relations

201.258.0361

201.847.6927

fallon.mcloughlin@bd.com

adam.reiffe@bd.com

Media for Penn Medicine:

Eric Horvath

Associate News Director

Penn Medicine

215-821-4289

Eric.horvath@pennmedicine.upenn.edu

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-penn-institute-for-immunology-and-immune-health-collaborate-to-advance-immunotherapy-through-flow-cytometry-302645260.html

SOURCE BD (Becton, Dickinson and Company)

Piyasa Fırsatı
FLOW Logosu
FLOW Fiyatı(FLOW)
$0.02973
$0.02973$0.02973
-0.06%
USD
FLOW (FLOW) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen crypto.news@mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Trump Approval Rating Tracker: 39% In Latest Survey

Trump Approval Rating Tracker: 39% In Latest Survey

The post Trump Approval Rating Tracker: 39% In Latest Survey appeared on BitcoinEthereumNews.com. Sept. 16-18 net approval rating: Trump’s favorability rating declined three points to 39% and the share of U.S. adults who have an unfavorable view of him increased two points to 57% compared to last week in an Economist/YouGov survey of 1,567 U.S. adults conducted Sept. 12-15 (margin of error 3.6). The results represent an 11-point decline in Trump’s 50% favorability rating at the start of his term, according to Economist/YouGov polling. Sept. 15-6 net approval rating: Trump’s job performance improved one point, to 46%, in Morning Consult’s weekly survey compared to the previous week, while his disapproval rating stayed stagnant at 52% (the poll of 2,204 registered U.S. voters was conducted Sept. 12-14 and has a margin of error of 2). The poll found the killing of conservative activist Charlie Kirk is the top story of 2025, with 67% of voters saying they’ve seen, read or heart “a lot” about it, according to Morning Consult, well above hundreds of other news events Morning Consult has asked about this year. Sept. 10-14: On par with two other polls this week, Trump had a 42% approval rating in the latest Reuters/Ipsos survey conducted Sept. 5-9, while 56% disapproved, representing a two-point increase from the groups’ August poll in his disapproval rating and a two-point uptick in his approval rating (the poll of 1,084 U.S. adults has a margin of error of 3). Sept. 8-7: Trump’s approval rating declined one point from last week, to 45%, tied with his record low since taking office, according to Morning Consult’s weekly survey that found 52% disapprove of his job performance (the poll of 2,201 registered voters conducted Sept. 6-8 has a margin of error of 2). Sept. 7-12: Trump’s approval rating ticked up two points from July, to 44%, while his disapproval rating declined two…
Paylaş
BitcoinEthereumNews2025/09/18 01:08
What Will Happen to the Price of Bitcoin If the U.S.-Iran War Ends? Here Are the Experts’ Predictions

What Will Happen to the Price of Bitcoin If the U.S.-Iran War Ends? Here Are the Experts’ Predictions

If the war between the US and Iran ends, what effect might this have on the price of Bitcoin? Here's what you need to know. Continue Reading: What Will Happen
Paylaş
Bitcoinsistemi2026/04/02 04:20
Iran threatens US tech firms, raising stakes in military escalation

Iran threatens US tech firms, raising stakes in military escalation

The post Iran threatens US tech firms, raising stakes in military escalation appeared on BitcoinEthereumNews.com. Iran’s threat to target US tech companies escalates
Paylaş
BitcoinEthereumNews2026/04/02 03:51

Trade GOLD, Share 1,000,000 USDT

Trade GOLD, Share 1,000,000 USDTTrade GOLD, Share 1,000,000 USDT

0 fees, up to 1,000x leverage, deep liquidity